Medical cannabis relieves symptoms in children with autism, study shows
Cannabis as a treatment for autism spectrum disorders appears to be a well-tolerated, safe, and effective option to relieve symptoms including seizures, tics, depression, restlessness, and rage attacks, according to a new study from the Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beersheba, Israel, published in the journal Scientific Reports.
The study included patients with autism who are 18 years old and under, and showed more than 80 percent of the parents reported significant or moderate improvement in their child, said Lihi Bar-Lev Schleider, MA, of the BGU-Soroka Clinical Cannabis Research Institute.
Autistic Spectrum Disorder (ASD) is an extensive developmental disorder that is expressed in almost all dimensions of the child's development. It is now common to refer to this disorder as a wide range of Pervasive Developmental Disorders (PDD) in which there are various manifestations and symptoms.
Researchers analyzed the data prospectively collected as part of the treatment program of 188 ASD patients treated with medical cannabis between 2015 and 2017. The treatment in the majority of the patients was based on cannabis oil containing 30 percent cannabidiol (CBD) and 1.5 percent tetrahydrocannabinol (THC). Symptoms, patient global assessment, and side effects at six months were primary outcomes of interest and were assessed by structured questionnaires.
Overall, after six months of treatment, 30 percent of patients reported a significant improvement, 53.7 percent reported moderate improvement, and 15 percent had slight or no change.
Quality of life, mood, and ability to perform activities of daily living were assessed prior to treatment and at six months. Good quality of life was reported by 31.3 percent of patients prior to treatment initiation. At six months, good quality of life more than doubled to 66.8 percent. Positive mood was reported as 42 percent before treatment and 63.5 after six months.
The ability to dress and shower independently improved significantly from cannabis treatment. Only a quarter (26.4 percent) reported no difficulty prior to the treatment while 42.9 percent improved their ability to dress and shower independently at six months.
Cannabis oil medication also significantly improved sleep and concentration. Good sleep and concentration were reported by 3.3 percent and zero percent respectively at the outset versus 24.7 percent and 14 percent during an active treatment.
While this study suggest that cannabis treatment is safe and can improve ASD symptoms and improve ASD patients' quality of life, researchers say that double blind placebo-controlled trials are crucial for a better understanding of the cannabis effect on ASD patients.